Shattuck Labs, INC

Shattuck Labs, Inc. announced the pricing of its underwritten public offering of common stock and pre-funded warrants, raising capital through the sale of over 18 million shares and warrants.

Shattuck Labs reports promising Phase 1 trial results for its SL-325 DR3 blocking antibody, with plans for a Phase 2b trial in Crohn's disease and advancement of its SL-846 bispecific candidate.

Shattuck Labs, Inc. announced the outcomes of its 2026 Annual Meeting of Stockholders, including the election of directors and approval of amendments to its 2020 Equity Incentive Plan.

Shattuck Labs announced Q1 2026 financial results, highlighting the completion of Phase 1 enrollment for SL-325 and providing an updated cash runway into 2029.

Shattuck Labs announced its full-year 2025 financial results, reporting reduced net losses and significant progress in its lead clinical program, SL-325.

Shattuck Labs, Inc. announced the date for its 2026 annual meeting of stockholders and revised deadlines for proposal submissions.

Shattuck Labs, Inc. filed its Q1 2026 10-Q, detailing a net loss of $14.8 million and continued progress in its SL-325 clinical trial, with cash reserves projected to fund operations into 2029.

Shattuck Labs reported a significant reduction in net loss for Q3 and the nine months ended September 30, 2025, driven by decreased R&D and G&A expenses, while securing $45.7 million in a private placement.

Shattuck Labs reports reduced Q2 2025 net loss and R&D expenses, secures a significant private placement of up to $103 million, and plans to initiate Phase 1 clinical trials for its lead candidate SL-325.

Shattuck Labs announces its Q1 2025 financial results, focusing on the advancement of its SL-325 program for inflammatory and immune-mediated diseases.

Shattuck Labs discontinues its SL-172154 program and focuses on its DR3 antagonist program, reporting a net loss of $56.7 million for the first nine months of 2024.

Shattuck Labs reported its second quarter 2024 financial results, highlighting progress in clinical trials and research collaborations.

Shattuck Labs, a clinical-stage biotech, is advancing its lead DR3 blocking antibody, SL-325, into Phase 2 for Crohn's Disease while reporting a reduced net loss for fiscal year 2025.

Shattuck Labs files an amendment to its 2024 Annual Report on Form 10-K/A solely to include certain XBRL interactive data that was inadvertently omitted in Amendment No. 1.

Shattuck Labs files an amendment to its 2024 Annual Report on Form 10-K/A to include information required by Items 10 through 14 of Part III, covering directors, executive compensation, security ownership, related transactions, and principal accountant fees.

Shattuck Labs' 2024 10-K filing highlights a strategic shift towards its SL-325 DR3 antagonist antibody program for inflammatory bowel disease, alongside financial results and risk factors.

Shattuck Labs details its 2020 Equity Incentive Plan and related stock option agreements, alongside its non-employee director compensation policy, in a recent SEC filing.

Shattuck Labs Chief Technical Officer Abhinav Shukla executed a series of transactions involving company stock and stock options, primarily under a pre-established Rule 10b5-1 trading plan.

Abhinav A. Shukla, Chief Technical Officer at Shattuck Labs, Inc., reported transactions involving the acquisition and sale of company common stock on June 30 and July 1, 2026, executed under a Rule 10b5-1 trading plan.

Shattuck Labs Chief Medical Officer, Arundathy N. Pandite, sold 30,000 shares of common stock for approximately $7.01 per share under a pre-established Rule 10b5-1 trading plan.

Director Mona Ashiya reports the acquisition of pre-funded warrants by OrbiMed-affiliated entities following a public offering.

OrbiMed Advisors acquired over 1.25 million pre-funded warrants in Shattuck Labs' recent public offering.

Director Clay B. Siegall purchased 62,500 shares of Shattuck Labs, Inc. common stock as part of a recent underwritten offering.

Shattuck Labs announces its 2026 Annual Meeting of Stockholders, detailing proposals including director elections, auditor ratification, executive compensation votes, and equity plan amendments.

Shattuck Labs will hold its annual stockholders meeting virtually on July 10, 2025, to elect directors and ratify the selection of KPMG LLP as the company's independent auditor.

Shattuck Labs will hold its 2025 Annual Meeting of Stockholders virtually on July 10, 2025, to vote on the election of directors and ratification of the independent auditor.

Shattuck Labs will hold its annual stockholders meeting on June 7, 2024, to elect directors and ratify the company's auditor.

Shattuck Labs will hold its 2024 Annual Meeting of Stockholders virtually on June 7, 2024, to elect directors and ratify the selection of its independent auditor.

Redmile Group, LLC and associated entities have updated their Schedule 13D filing, reporting a beneficial ownership of 9.9% in Shattuck Labs, Inc. as of July 17, 2026.

OrbiMed Advisors filed an amended Schedule 13D reporting its beneficial ownership in Shattuck Labs following a recent public offering.

Redmile Group, LLC and affiliates increased their beneficial ownership in Shattuck Labs, Inc. through warrant exercises and participation in an underwritten offering.

OrbiMed Advisors and its affiliates have acquired a significant stake in Shattuck Labs, Inc. through a private placement, increasing their beneficial ownership to 9.99%.

Redmile Group, LLC increased its beneficial ownership in Shattuck Labs, Inc. to 9.9% following a private placement, while its managing director, Mike Lee, resigned from the board.

Shattuck Labs, Inc. has entered into a private placement agreement with Redmile Group, LLC, granting Redmile significant equity and board observer rights contingent on FDA clearance.

Deep Track Capital, LP, along with its affiliates, has reported beneficial ownership of 5,000,033 shares, representing 5.17% of the outstanding common stock of Shattuck Labs, Inc.

T. Rowe Price Investment Management, Inc. has reported a significant 11.7% beneficial ownership stake in Shattuck Labs Inc. common stock.

Prosight Management and its affiliates have reported a 9.9% beneficial ownership stake in Shattuck Labs, Inc., including shares and exercisable warrants.

The Vanguard Group has filed an amended Schedule 13G, disclosing a reduced beneficial ownership of 4.48% in Shattuck Labs Inc.'s common stock.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a passive beneficial ownership of 1.8% of Shattuck Labs, Inc.'s common stock as of June 30, 2025.

Adage Capital Management, L.P. and its principals, Robert Atchinson and Phillip Gross, have disclosed a significant beneficial ownership of 9.79% in Shattuck Labs, Inc. as of December 31, 2024.